Patents Examined by Jerome D. Goldberg
  • Patent number: 6727235
    Abstract: According to the invention, compositions are made available which have a strong cytotoxic effect which is largely selective on tumor tissue. The invention is based on the fact that certain benzoic acid derivatives have a strong synergistic effect as a mixture and destroy cancer cells selectively in a pH range of 7 or below, such as from 6.5 to 7.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: April 27, 2004
    Inventor: Werner Kreutz
  • Patent number: 6726908
    Abstract: This invention relates to pharmaceutical formulations comprising amoxycillin and a salt clavulanic acid in a ratio of 14:1.
    Type: Grant
    Filed: October 27, 1997
    Date of Patent: April 27, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventor: Daniel Joseph Burch
  • Patent number: 6723712
    Abstract: The invention relates to an antiviral agent for use in combination with an anticancer agent, for the treatment of cancer. Especially, the invention provides means for the treatment of non-virus-associated cancer.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: April 20, 2004
    Assignees: Institut Gustave Roussy, Universite Paris-SUD XI
    Inventors: Jean Bourhis, Bassam Abdulkarim, Eric Deutsch
  • Patent number: 6706714
    Abstract: This invention provides compounds of formula I, R is hydrogen or alkyl of 1-6 carbon atoms; R′ is hydrogen, alkyl of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; R1, R2, R3, and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, trifluoroalkyl, —CN, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, trifluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl; X is CR5R6 or a carbonyl group; R5 and R6 are each, independently, hydrogen or alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, with the proviso that at least one of R1, R2, R3, or R4 are not hydrogen; which are 5HT2C receptor agonists useful for the treatment of disorders involving the central nervous system such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorders, eatin
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: March 16, 2004
    Inventors: Annmarie Louise Sabb, Gregory Scott Welmaker, James Albert Nelson
  • Patent number: 6703380
    Abstract: The present invention relates to a method for the prevention of cancer or the initiation and/or progression of cancer in a human comprising administration to the human a combination dosage of a cyclooxygenase (COX) inhibitor, a vitamin D3 including analogues and metabolites thereof and calcium. In a further embodiment the invention relates to the use of the combination dosage for the preparation of a medicament and to such pharmaceutical preparations. In a further aspect the invention relates to a method for reducing the effective dosage of ASA in a chemoprofylactive treatment of colorectal cancer in a human by co-administration with a non toxic dosage of a vitamin D3 including analogues and metabolites thereof and Ca in the form of a combination dosage.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: March 9, 2004
    Assignees: Colotech A/S
    Inventor: Hans Henrik Raskov
  • Patent number: 6696478
    Abstract: A chemotheraputic cancer treatment in which Gö6976 or a compound chemically similar to Gö6976 is administered to a mammal for the treatment of the cancer. The chemical compound is targeted to PKC &agr; activity. Experiments have shown Gö6976 and similar compounds to be effective for the treatment of breast cancer, leukemia, lung cancer, bone cancer, skin cancer, prostate cancer, liver cancer, brain tumor, cervical cancer, and cancers located in the digestive tract including gastric cancer and colorectal cancers. These treatments may be accomplished utilizing Gö6976 and compounds similar to it alone or in combination with prior art chemotherapy agents or with radiation therapy. In a preferred embodiment Gö6976 is used for the treatment of cancer as a preventative drug by preventing cancer cell formation.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: February 24, 2004
    Inventors: Zhimin Lu, Keming Wang
  • Patent number: 6696428
    Abstract: The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: February 24, 2004
    Assignee: Zentaris AG
    Inventors: Bernd Nickel, Peter Hilgard, Thomas Klenner, Jürgen Engel
  • Patent number: 6693127
    Abstract: Pharmaceutical compositions containing arglabin and arglabin derivatives are described. The compositions can be in unit dosage form and are useful for the treatment of cancer in humans.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: February 17, 2004
    Assignee: Paracure, Inc.
    Inventor: Sergazy M. Adekenov
  • Patent number: 6693119
    Abstract: The invention relates to the use of N-substituted indole-3-glyoxylamides of the general Formula I and to pharmaceutical compositions having antitumor action.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: February 17, 2004
    Assignee: Baxter Healthcare SA
    Inventors: Bernd Nickel, Gerald Bacher, Thomas Klenner, Thomas Beckers, Peter Emig, Jürgen Engel, Erik Bruyneel, Günter Kamp, Kirsten Peters
  • Patent number: 6693104
    Abstract: Disclosed is theobromine with an anti-carcinogenic activity which inhibits the suppression of GJIC (gap junctional intercellular communication), a pathological phenomenon occurring during development of various kinds of cancers including liver cancer, as well as DNA synthesis of cancer cells thereby inhibiting proliferation of liver, gastric and colon cancer cells.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: February 17, 2004
    Assignee: Lotte Confectionery Co., Ltd.
    Inventors: Hyong Joo Lee, Ki Won Lee, Kyung Sun Kang, Dong Young Kim, Hyung Hwan Park, Man Jong Lee, Han Soo Kim, Ik Boo Kwon
  • Patent number: 6693125
    Abstract: The invention features a method for treating a patient having a cancer or other neoplasm, by administering to the patient (i) a benzimidazole or a metabolite or analog thereof; and (ii) pentamidine or a metabolite or analog thereof simultaneously or within 14 days of each other in amounts sufficient to inhibit the growth of the neoplasm.
    Type: Grant
    Filed: January 24, 2001
    Date of Patent: February 17, 2004
    Assignee: CombinatoRx Incorporated
    Inventors: Alexis Borisy, Curtis Keith, Michael A. Foley, Brent R. Stockwell
  • Patent number: 6689815
    Abstract: Dinitrohalogenated compounds may be utilized by injection in certain clinical situations to provide a possibility of long term control of human malignancy. In some of those settings no other treatment offers such potential. Preparation methods may include acetone, olive oil, microsomes, liposomes, or combinations thereof. Optimum pretreatment management, dosing and injection techniques are described. The unique aspects of the claims included herein include the methods of preparation of the chemical, the technique of injection, the dosage of each injection, and the range of potential tumor histologies. These techniques have resulted for example in successful treatment of locally metastatic scalp melanoma, the treatment for which had previously been uniformly unsuccessful. This example is particularly significant since this is one example of a site that is not otherwise amenable to successful treatment when affected by multiple progressive metastatic nodules.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: February 10, 2004
    Inventor: Max Harry Cohen
  • Patent number: 6689812
    Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: February 10, 2004
    Assignee: Laxdale Limited
    Inventors: Malcolm Peet, Krishna S Vaddadi
  • Patent number: 6686391
    Abstract: Methods for the treatment of cancers or viral infections in mammals are disclosed that include administration of an N-chlorophenylcarbamate, or an N-chlorophenylthiocarbamate, or a salt thereof. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: February 3, 2004
    Assignee: University of Arizona Foundation
    Inventor: James Berger Camden
  • Patent number: 6683100
    Abstract: Pharmaceutical formulations comprising an epothilone in the form of an infusion concentrate or a lyophilised composition, and methods of administration of an epothilone in suitable form for parenteral administration.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: January 27, 2004
    Assignee: Novartis AG
    Inventor: Peter van Hoogevest
  • Patent number: 6676973
    Abstract: A method is provided for treating an ovarian cancer in a human or other mammalian patient suffering from the ovarian cancer, the method comprises administering to the human or the other mammalian patient an effective ovarian cancer treating amount of cadmium, preferably in the form of cadmium chloride. Pharmaceutical compositions and pharmaceutical kits which are useful in practicing the described method of treating ovarian cancer in the human or other mammalian patient suffering from the ovarian cancer are also provided for in the disclosure.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: January 13, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Kang Bo Lee, Ricardo J. Parker, Eddie Reed
  • Patent number: 6677370
    Abstract: Dictyostatin-1 has been found to stabilize microtubules and prohibit their depolymerization to free tubulin. Because of these activities, the dictyostatin compounds can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: January 13, 2004
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Amy E. Wright, Jennifer L. Cummins, Shirley A. Pomponi, Ross E. Longley, Richard A. Isbrucker
  • Patent number: 6673813
    Abstract: This invention provides a method of identifying and reversing multidrug resistance in a multidrug resistant tumor comprising administering a multidrug resistance reversing amount of any of the compounds as defined herein.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: January 6, 2004
    Inventors: Gabriele Jedlitschky, Inka Leier, Dietrich Keppler
  • Patent number: 6667337
    Abstract: This invention relates to a method of treating cancer, and particularly a method including the steps of administering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a compound selected from a paclitaxel and docetaxel, and (ii) a compound of the formula or a pharmaceutically acceptable salt or ester thereof; wherein R1, R2 and R3 are each independently selected from the group consisting of H, C1-C6 alkyl, halogen, CF3, CN, NO2, NH2, OH, OR, NHCOR, NHSO2R, SR, SO2R or NHR, wherein each R is independently C1-C6 alkyl optionally substituted with one or more substituents selected from hydroxy, amino and methoxy, and wherein each of R1, R2 and R3 may be present at any of the available positions 1 to 8; and wherein in each of the carbocyclic aromatic rings in formula (I), up to two of the methine (—CH═) groups may be replaced by an aza (—N═) group; and wherein any two of R1, R2 and R3 may additionally together represent the group —CH
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: December 23, 2003
    Assignee: Cancer Research Technology Limited
    Inventor: William R. Wilson
  • Patent number: 6664285
    Abstract: The present invention relates to the use of cell membrane penetrating indigoid bisindole derivatives for the manufacture of a medicament for the treatment of human solid cancers.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: December 16, 2003
    Inventors: Gerhard Eisenbrand, Heinz Herbert Fiebig, Doris Marko, Ralf Hössel, Weici Tang